| Bioactivity | KRAS G12D inhibitor 20 (Compound 14) is a selective G12D KRAS inhibitor. KRAS G12D inhibitor 20 has antitumor activity[1]. |
| Invitro | KRAS G12D inhibitor 20 (72 h) shows antiproliferative activity against PANC-1 (KRAS G12D) and BxPC3 (KRASwt) human pancreatic cancer cell lines, with IC50s of 5.5 and 8.2 μM, and is low toxic for normal cells[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> KRAS G12D inhibitor 20 相关抗体: |
| In Vivo | KRAS G12D inhibitor 20 (6 mg/kg, i.p., 6 injections) has no significant change in body weight in healthy BALB/c female mice[1].KRAS G12D inhibitor 20 (6 mg/kg, i.p.) reduces tumor volume by 13.1% in xenograft mouse models using immunodeficient SCID male mice bearing KRASG12D (PANC-1)[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| Formula | C18H26N6O |
| Molar Mass | 342.44 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ranđelović I, ,et al. Gluing GAP to RAS Mutants: A New Approach to an Old Problem in Cancer Drug Development. Int J Mol Sci. 2024 Feb 22;25(5):2572. |